US2023040805A1PendingUtilityA1

Ionic liquids for internal delivery

69
Assignee: HARVARD COLLEGEPriority: Nov 17, 2017Filed: Jun 28, 2022Published: Feb 9, 2023
Est. expiryNov 17, 2037(~11.3 yrs left)· nominal 20-yr term from priority
Inventors:Samir MitragotriAmrita BanerjeeTyler BrownKelly IbsenChristian Agatemor
A61K 47/12A61K 38/26A61P 43/00A61K 31/4745A61K 9/0053A61K 31/14A61K 38/28A61K 9/0034A61P 35/04A61K 9/4891A61K 31/337A61K 31/201A61P 35/00A61K 9/0043A61P 3/10A61K 9/4858A61P 3/04A61K 9/0019A61P 17/02A61K 9/48A61K 47/186
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The technology described herein is directed to compositions comprising CAGE and at least one active compound, e.g., for oral or parenteral administration.

Claims

exact text as granted — not AI-modified
1 .- 142 . (canceled) 
     
     
         143 . A method of delivery of at least one active compound to a subject in need thereof, the method comprising intratumorally administering a composition comprising Choline and Geranate or Geranic Acid (CAGE) in combination with the at least one active compound to the subject. 
     
     
         144 . The method of  claim 143 , wherein the CAGE is at a concentration of at least 0.1% w/v. 
     
     
         145 . The method of  claim 143 , wherein the CAGE comprises a ratio of Choline:Geranate or Geranic Acid of from about 2:1 to about 1:10. 
     
     
         146 . The method of  claim 143 , wherein the at least one active compound comprises a nucleic acid molecule, a small molecule, a polypeptide, an antibody, an antibody reagent, or a chemotherapeutic compound. 
     
     
         147 . The method of  claim 143 , wherein the composition further comprises a pharmaceutically acceptable carrier. 
     
     
         148 . The method of  claim 143 , wherein the combination of the at least one active compound and CAGE is an admixture. 
     
     
         149 . The method of  claim 143 , wherein the delivery is into a tumor in the subject. 
     
     
         150 . The method of  claim 143 , wherein the CAGE comprises a ratio of Choline:Geranate or Geranic Acid of from about 1:1 to about 1:4. 
     
     
         151 . The method of  claim 143 , wherein the CAGE comprises a ratio of Choline:Geranate or Geranic Acid of from about 1:2 to about 1:5. 
     
     
         152 . The method of  claim 143 , wherein the at least one active compound is administered once. 
     
     
         153 . The method of  claim 143 , wherein the at least one active compound is administered in multiple doses. 
     
     
         154 . The method of  claim 146 , wherein the at least one active compound comprises a chemotherapeutic compound. 
     
     
         155 . The method of  claim 143 , wherein the at least one active compound is provided at a dosage of 1-20 mg/kg.

Join the waitlist — get patent alerts

Track US2023040805A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.